MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Leucine-rich alpha-2-glycoprotein (LRG1) is an abundant serum protein that has emerged as a critical modulator of diverse signalling pathways implicated in disease mechanisms. Predominantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback